CA3146947A1 - Nmr measurements of glyca - Google Patents
Nmr measurements of glycaInfo
- Publication number
- CA3146947A1 CA3146947A1 CA3146947A CA3146947A CA3146947A1 CA 3146947 A1 CA3146947 A1 CA 3146947A1 CA 3146947 A CA3146947 A CA 3146947A CA 3146947 A CA3146947 A CA 3146947A CA 3146947 A1 CA3146947 A1 CA 3146947A1
- Authority
- CA
- Canada
- Prior art keywords
- glyca
- nmr
- risk
- hdl
- valine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000005481 NMR spectroscopy Methods 0.000 title description 121
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 89
- 239000004474 valine Substances 0.000 claims description 89
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 72
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 50
- 102000004895 Lipoproteins Human genes 0.000 claims description 42
- 108090001030 Lipoproteins Proteins 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 33
- 238000004458 analytical method Methods 0.000 claims description 28
- 235000004252 protein component Nutrition 0.000 claims description 8
- 238000003908 quality control method Methods 0.000 claims description 5
- 238000005259 measurement Methods 0.000 abstract description 71
- 230000034994 death Effects 0.000 abstract description 44
- 231100000517 death Toxicity 0.000 abstract description 44
- 208000029078 coronary artery disease Diseases 0.000 abstract description 43
- 201000010099 disease Diseases 0.000 abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 31
- 206010061218 Inflammation Diseases 0.000 abstract description 22
- 230000004054 inflammatory process Effects 0.000 abstract description 22
- 239000000090 biomarker Substances 0.000 abstract description 14
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 abstract description 10
- 238000012502 risk assessment Methods 0.000 abstract description 8
- 206010012289 Dementia Diseases 0.000 abstract description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 2
- 230000006870 function Effects 0.000 description 49
- 239000000523 sample Substances 0.000 description 48
- 108010010234 HDL Lipoproteins Proteins 0.000 description 43
- 102000015779 HDL Lipoproteins Human genes 0.000 description 43
- 210000002381 plasma Anatomy 0.000 description 40
- 108010007622 LDL Lipoproteins Proteins 0.000 description 39
- 102000007330 LDL Lipoproteins Human genes 0.000 description 39
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 34
- 239000002245 particle Substances 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 29
- 239000002131 composite material Substances 0.000 description 28
- 238000001228 spectrum Methods 0.000 description 27
- 238000011156 evaluation Methods 0.000 description 26
- 239000000126 substance Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 108010004103 Chylomicrons Proteins 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 18
- 239000002207 metabolite Substances 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 102000003886 Glycoproteins Human genes 0.000 description 16
- 108090000288 Glycoproteins Proteins 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 238000004590 computer program Methods 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 238000012545 processing Methods 0.000 description 13
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 12
- 230000000391 smoking effect Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 102100032752 C-reactive protein Human genes 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 238000004891 communication Methods 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 230000035488 systolic blood pressure Effects 0.000 description 8
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 7
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 7
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 229950006780 n-acetylglucosamine Drugs 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 6
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 6
- 238000005284 basis set Methods 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 125000003047 N-acetyl group Chemical group 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000012417 linear regression Methods 0.000 description 5
- 238000007477 logistic regression Methods 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000000079 presaturation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 101100228149 Drosophila melanogaster Trl gene Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 101100370408 Helicobacter pylori (strain ATCC 700392 / 26695) trl gene Proteins 0.000 description 2
- 108010046315 IDL Lipoproteins Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000002124 flame ionisation detection Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
- 101000860173 Myxococcus xanthus C-factor Proteins 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- OPFMNOHTGRIQDK-UHFFFAOYSA-N [Ca].CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCN Chemical compound [Ca].CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCN OPFMNOHTGRIQDK-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- KBGAYAKRZNYFFG-BOHATCBPSA-N aceneuramic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](NC(=O)C)[C@@H](O)[C@H](O)[C@H](O)CO KBGAYAKRZNYFFG-BOHATCBPSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000358 protein NMR Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013058 risk prediction model Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QVSRWXFOZLIWJS-UHFFFAOYSA-N trimethylsilyl propanoate Chemical compound CCC(=O)O[Si](C)(C)C QVSRWXFOZLIWJS-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
- A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
- A61B5/0044—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/46—NMR spectroscopy
- G01R33/4625—Processing of acquired signals, e.g. elimination of phase errors, baseline fitting, chemometric analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/46—NMR spectroscopy
- G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2576/00—Medical imaging apparatus involving image processing or analysis
- A61B2576/02—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part
- A61B2576/023—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part for the heart
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- High Energy & Nuclear Physics (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Signal Processing (AREA)
- Hematology (AREA)
- Radiology & Medical Imaging (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Ecology (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Cardiology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657315P | 2012-06-08 | 2012-06-08 | |
| US61/657,315 | 2012-06-08 | ||
| US201261711471P | 2012-10-09 | 2012-10-09 | |
| US61/711,471 | 2012-10-09 | ||
| US201261739305P | 2012-12-19 | 2012-12-19 | |
| US61/739,305 | 2012-12-19 | ||
| US13/830,199 US9470771B2 (en) | 2012-06-08 | 2013-03-14 | NMR measurements of NMR biomarker GlycA |
| US13/830,199 | 2013-03-14 | ||
| CA2874550A CA2874550C (en) | 2012-06-08 | 2013-05-30 | Nmr measurements of glyca |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2874550A Division CA2874550C (en) | 2012-06-08 | 2013-05-30 | Nmr measurements of glyca |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3146947A1 true CA3146947A1 (en) | 2013-12-12 |
Family
ID=49712504
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3146947A Pending CA3146947A1 (en) | 2012-06-08 | 2013-05-30 | Nmr measurements of glyca |
| CA2874550A Active CA2874550C (en) | 2012-06-08 | 2013-05-30 | Nmr measurements of glyca |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2874550A Active CA2874550C (en) | 2012-06-08 | 2013-05-30 | Nmr measurements of glyca |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9470771B2 (enExample) |
| EP (3) | EP4439587A3 (enExample) |
| JP (1) | JP6177899B2 (enExample) |
| CN (1) | CN104508471B (enExample) |
| AU (1) | AU2013272014B2 (enExample) |
| CA (2) | CA3146947A1 (enExample) |
| FI (1) | FI3839544T3 (enExample) |
| SG (1) | SG11201407803TA (enExample) |
| WO (1) | WO2013184483A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9076342B2 (en) | 2008-02-19 | 2015-07-07 | Architecture Technology Corporation | Automated execution and evaluation of network-based training exercises |
| US9928345B2 (en) * | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US9361429B2 (en) | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| US20140358451A1 (en) * | 2013-06-04 | 2014-12-04 | Arizona Board Of Regents On Behalf Of Arizona State University | Fractional Abundance Estimation from Electrospray Ionization Time-of-Flight Mass Spectrum |
| CN106415276B (zh) * | 2013-11-27 | 2018-10-16 | 威尔吉利健康研究所 | 用于表征脂蛋白的方法 |
| EP3058369B1 (en) * | 2014-01-06 | 2020-06-17 | Liposcience, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| CN107110939B (zh) * | 2014-09-11 | 2021-05-14 | 力保科学公司 | 用于测定心血管疾病或事件的风险参数的系统 |
| JP6442053B2 (ja) | 2014-10-31 | 2018-12-19 | 華為技術有限公司Ｈｕａｗｅｉ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｃｏ．，Ｌｔｄ． | 曲線当てはめ回路、アナログ前置補償器、および無線周波数信号送信器 |
| US10803766B1 (en) | 2015-07-28 | 2020-10-13 | Architecture Technology Corporation | Modular training of network-based training exercises |
| US10083624B2 (en) | 2015-07-28 | 2018-09-25 | Architecture Technology Corporation | Real-time monitoring of network-based training exercises |
| EP3258285B1 (en) * | 2016-06-14 | 2020-10-21 | Bruker BioSpin GmbH | Method for predicting chemical shift values of nmr spin systems in a sample of a fluid class, in particular in a sample of a biofluid |
| DE102016224691A1 (de) * | 2016-12-12 | 2018-06-14 | Numares Ag | Verfahren zur Analyse eines NMR-Spektrums einer lipoproteinhaltigen Probe |
| FI20177098A1 (fi) * | 2017-08-29 | 2019-03-01 | Leppaeluoto Juhani | Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen |
| WO2019051226A1 (en) | 2017-09-07 | 2019-03-14 | Liposcience, Inc. | METABOLIC VULNERABILITY INDEX ASSESSMENTS WITH MULTIPLE PARAMETERS |
| CN107796946B (zh) * | 2017-10-20 | 2019-10-25 | 中国医学科学院基础医学研究所 | 尿液中冠心病的蛋白标志物及其用途 |
| WO2019094879A1 (en) * | 2017-11-10 | 2019-05-16 | Liposcience, Inc. | Methods and systems to detect and quantify the amount of lp-x and other abnormal lipoproteins in a biosample using nmr spectroscopy |
| WO2019143801A1 (en) * | 2018-01-18 | 2019-07-25 | New York University | System and method for blood glucose monitoring using magnetic resonance spectroscopy |
| CN109805898B (zh) * | 2019-03-22 | 2024-04-05 | 中国科学院重庆绿色智能技术研究院 | 基于注意力机制时序卷积网络算法的危重症死亡预测方法 |
| US11887505B1 (en) | 2019-04-24 | 2024-01-30 | Architecture Technology Corporation | System for deploying and monitoring network-based training exercises |
| EP4281768A1 (en) * | 2021-01-22 | 2023-11-29 | Bruker BioSpin MRI GmbH | Infection diagnosis and characterization using diffusion and relaxation edited proton nmr spectroscopy |
| US20240044826A1 (en) * | 2022-08-05 | 2024-02-08 | Liposcience, Inc. | Metabolic vulnerability analyzed by nmr |
| DE102023110285B3 (de) | 2023-04-21 | 2024-05-08 | Universität zu Lübeck, Körperschaft des öffentlichen Rechts | Nmr-messung von glykoproteinen |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529710A (en) | 1981-06-12 | 1985-07-16 | The United States Of America As Represented By The United States Department Of Energy | Method of using a nuclear magnetic resonance spectroscopy standard |
| JPH0698036B2 (ja) | 1986-10-20 | 1994-12-07 | 小野薬品工業株式会社 | アミノ酸の選択的定量法 |
| US4933844A (en) | 1988-09-26 | 1990-06-12 | Otvos James D | Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer |
| WO2000051054A1 (en) | 1999-02-26 | 2000-08-31 | Lipomed, Inc. | Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood |
| US6653140B2 (en) * | 1999-02-26 | 2003-11-25 | Liposcience, Inc. | Methods for providing personalized lipoprotein-based risk assessments |
| CA2367820C (en) | 1999-04-22 | 2009-12-22 | James D. Otvos | Nmr-method for determining the risk of developing type 2 diabetes |
| CA2331116A1 (en) | 2001-01-15 | 2002-07-15 | Chenomx, Inc. | Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system |
| WO2003012416A1 (en) | 2001-08-01 | 2003-02-13 | Liposcience, Inc. | Method of determining presence and concentration of lipoprotein x in blood plasma and serum |
| WO2003107270A2 (en) | 2002-06-14 | 2003-12-24 | Pfizer Limited | Metabolic phenotyping |
| US7243030B2 (en) | 2002-10-25 | 2007-07-10 | Liposcience, Inc. | Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals |
| WO2004085996A2 (en) | 2003-03-20 | 2004-10-07 | Albert Einstein College Of Medicine Of Yeshiva University | Biomarkers for longevity and disease and uses thereof |
| CA2542107A1 (en) | 2003-10-23 | 2005-05-12 | Liposcience, Inc. | Methods, systems and computer programs for assessing chd risk using mathematical models that consider in vivo concentration gradients of ldl particle subclasses of discrete size |
| AU2005230449B2 (en) | 2004-04-01 | 2010-02-18 | Liposcience, Inc. | NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples |
| WO2006057081A1 (en) | 2004-11-24 | 2006-06-01 | Mitsuyo Okazaki | Method for analyzing lipoproteins |
| JP5006524B2 (ja) | 2005-05-13 | 2012-08-22 | 株式会社日立製作所 | 緩和時間特定のためのｎｍｒ装置の信号処理方法 |
| JP4358814B2 (ja) | 2005-11-09 | 2009-11-04 | 花王株式会社 | 試料の解析方法 |
| DE602007011592D1 (de) | 2006-03-24 | 2011-02-10 | Metanomics Gmbh | MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES typ II |
| WO2007133593A2 (en) | 2006-05-10 | 2007-11-22 | Liposcience, Inc. | Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements |
| WO2008137075A2 (en) | 2007-05-02 | 2008-11-13 | President And Fellows Of Harvard College | Compositions and methods for the treatment of metabolic disorders and inflammation |
| US7923257B2 (en) | 2007-05-04 | 2011-04-12 | Perkinelmer Health Sciences, Inc. | Detecting isomers using differential derivatization mass spectrometry |
| EP2019311A1 (en) | 2007-07-23 | 2009-01-28 | F.Hoffmann-La Roche Ag | A method for detecting a target substance by nuclear magnetic resonance |
| WO2010005982A2 (en) | 2008-07-07 | 2010-01-14 | The General Hospital Corporation | Multiplexed biomarkers of insulin resistance |
| EP2344890B1 (en) | 2008-10-20 | 2021-08-11 | Liposcience, Inc. | Lipoprotein insulin resistance indexes and related methods |
| WO2010114897A1 (en) | 2009-03-31 | 2010-10-07 | Metabolon, Inc. | Biomarkers related to insulin resistance and methods using the same |
| US8741788B2 (en) | 2009-08-06 | 2014-06-03 | Applied Materials, Inc. | Formation of silicon oxide using non-carbon flowable CVD processes |
| US7935643B2 (en) | 2009-08-06 | 2011-05-03 | Applied Materials, Inc. | Stress management for tensile films |
| US8449942B2 (en) | 2009-11-12 | 2013-05-28 | Applied Materials, Inc. | Methods of curing non-carbon flowable CVD films |
| US20110136241A1 (en) | 2009-12-08 | 2011-06-09 | Stephen Naylor | Type ii diabetes molecular bioprofile and method and system of using the same |
| CN102754193A (zh) | 2010-01-06 | 2012-10-24 | 应用材料公司 | 使用氧化物衬垫的可流动电介质 |
| CA2799757C (en) | 2010-05-21 | 2018-12-04 | The Governors Of The University Of Alberta | Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US9361429B2 (en) | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| CA2887475C (en) | 2012-10-09 | 2021-12-14 | Liposcience, Inc. | Nmr quantification of branched chain amino acids |
-
2013
- 2013-03-14 US US13/830,199 patent/US9470771B2/en active Active
- 2013-05-30 CN CN201380041876.4A patent/CN104508471B/zh active Active
- 2013-05-30 JP JP2015516071A patent/JP6177899B2/ja active Active
- 2013-05-30 EP EP24189279.3A patent/EP4439587A3/en active Pending
- 2013-05-30 CA CA3146947A patent/CA3146947A1/en active Pending
- 2013-05-30 EP EP13800239.9A patent/EP2859339B1/en active Active
- 2013-05-30 WO PCT/US2013/043343 patent/WO2013184483A1/en not_active Ceased
- 2013-05-30 AU AU2013272014A patent/AU2013272014B2/en active Active
- 2013-05-30 CA CA2874550A patent/CA2874550C/en active Active
- 2013-05-30 FI FIEP20199970.3T patent/FI3839544T3/fi active
- 2013-05-30 EP EP20199970.3A patent/EP3839544B1/en active Active
- 2013-05-30 SG SG11201407803TA patent/SG11201407803TA/en unknown
-
2016
- 2016-09-14 US US15/264,977 patent/US10852293B2/en active Active
-
2020
- 2020-11-13 US US17/097,640 patent/US11692995B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20130328561A1 (en) | 2013-12-12 |
| AU2013272014A1 (en) | 2014-12-18 |
| EP4439587A2 (en) | 2024-10-02 |
| FI3839544T3 (fi) | 2024-12-27 |
| CA2874550A1 (en) | 2013-12-12 |
| EP2859339B1 (en) | 2020-10-28 |
| US20170003269A1 (en) | 2017-01-05 |
| EP3839544A1 (en) | 2021-06-23 |
| CA2874550C (en) | 2022-04-19 |
| WO2013184483A1 (en) | 2013-12-12 |
| US9470771B2 (en) | 2016-10-18 |
| CN104508471A (zh) | 2015-04-08 |
| EP3839544B1 (en) | 2024-10-02 |
| HK1207156A1 (en) | 2016-01-22 |
| JP2015522806A (ja) | 2015-08-06 |
| SG11201407803TA (en) | 2014-12-30 |
| EP4439587A3 (en) | 2024-12-18 |
| US11692995B2 (en) | 2023-07-04 |
| US10852293B2 (en) | 2020-12-01 |
| EP2859339A1 (en) | 2015-04-15 |
| JP6177899B2 (ja) | 2017-08-09 |
| EP2859339A4 (en) | 2016-08-03 |
| AU2013272014B2 (en) | 2017-05-25 |
| US20210080452A1 (en) | 2021-03-18 |
| CN104508471B (zh) | 2017-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11692995B2 (en) | NMR measurements of NMR biomarker GlycA | |
| US20240096497A1 (en) | Multi-Parameter Diabetes Risk Evaluations | |
| US20220137076A1 (en) | Cardiovascular Risk Evaluations Using a Risk Parameter That Includes an HDL and Inflammatory Biomarker Interaction Parameter | |
| HK40055406A (en) | Nmr measurements of glyca for determining coronary heart disease risk | |
| HK40055406B (en) | Nmr measurements of glyca for determining coronary heart disease risk | |
| HK1207156B (en) | Nmr measurements of glyca | |
| HK40108481A (en) | Multi-parameter diabetes risk evaluations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |
|
| EEER | Examination request |
Effective date: 20220127 |